CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
髓系恶性肿瘤的固有免疫机制与免疫治疗
英文原题：Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies.
查看英文原题
Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
与其他癌症类似，髓系恶性肿瘤在发生过程中也会逃避免疫系统。这种免疫逃逸既可由恶性细胞自身机制造成，也可由细胞外机制介导，并涉及对先天和适应性免疫系统的调控。研究者正在探索多种策略，以恢复、重定向或增强免疫系统对抗髓系恶性肿瘤。目前较成功的策略包括干扰素治疗和抗体疗法；嵌合抗原受体（CAR）细胞及免疫检查点抑制剂也显示出前景。本文综述抵御髓系恶性肿瘤的固有免疫机制、目前已获批药物及正在研究的药物，并总体评估免疫肿瘤学策略用于髓系恶性肿瘤治疗的疗效和潜力。
展开英文摘要原文
Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies.
So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation.
Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.
论文信息
- 作者
- Small S、Numan Y、Platanias LC
- 单位
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.United States
- 文献类型
- 综述
- 期刊
- Biomedicines2021 Nov 6
- 原文标识
- PubMed 34829860 · DOI 10.3390/biomedicines9111631
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →